JUNS Fundamental Analysis - JUPITER NEUROSCIENCES INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to JUNS. JUNS was compared to 196 industry peers in the Pharmaceuticals industry. While JUNS seems to be doing ok healthwise, there are quite some concerns on its profitability. JUNS does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year JUNS has reported negative net income.

In the past year JUNS has reported a negative cash flow from operations.

JUNS had negative earnings in each of the past 5 years.

JUNS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -77.13%, JUNS is not doing good in the industry: 69.90% of the companies in the same industry are doing better.

JUNS has a Return On Equity of -114.66%. This is in the lower half of the industry: JUNS underperforms 61.73% of its industry peers.

		Industry Rank	Sector Rank
ROA	-77.13%
ROE	-114.66%
ROIC	N/A

ROA(3y)-1983.37%

ROA(5y)-11078.3%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

JUNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

JUNS has more shares outstanding than it did 1 year ago.

The number of shares outstanding for JUNS has been increased compared to 5 years ago.

JUNS has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 6.99 indicates that JUNS is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 6.99, JUNS belongs to the best of the industry, outperforming 83.16% of the companies in the same industry.

A Debt/Equity ratio of 0.04 indicates that JUNS is not too dependend on debt financing.

JUNS has a Debt to Equity ratio (0.04) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Altman-Z	6.99

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 2.31 indicates that JUNS has no problem at all paying its short term obligations.

JUNS has a Current ratio (2.31) which is in line with its industry peers.

A Quick Ratio of 2.31 indicates that JUNS has no problem at all paying its short term obligations.

The Quick ratio of JUNS (2.31) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.31
Quick Ratio	2.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

JUNS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.

The Revenue for JUNS has decreased by -100.00% in the past year. This is quite bad

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-383%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, JUNS will show a very negative growth in Earnings Per Share. The EPS will decrease by -19.51% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y66%

EPS Next 2Y-30.38%

EPS Next 3Y40.07%

EPS Next 5Y-19.51%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

JUNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year JUNS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

JUNS's earnings are expected to grow with 40.07% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-30.38%

EPS Next 3Y40.07%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for JUNS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (9/24/2025, 8:14:00 PM)

Premarket: 1.4 0 (0%)

1.4

+0.05 (+3.7%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)08-19 2025-08-19/bmo

Earnings (Next)N/A N/A

Inst Owners1.17%

Inst Owner Change-78.87%

Ins Owners49.23%

Ins Owner Change0.09%

Market Cap48.76M

Analysts82.86

Price Target30.6 (2085.71%)

Short Float %1.19%

Short Ratio0.69

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	11.69
P/tB	11.69
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.25

Fwd EYN/A

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0

BVpS0.12

TBVpS0.12

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-77.13%
ROE	-114.66%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-1983.37%

ROA(5y)-11078.3%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.04
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.31
Quick Ratio	2.31
Altman-Z	6.99

F-ScoreN/A

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)0%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-383%

EPS Next Y66%

EPS Next 2Y-30.38%

EPS Next 3Y40.07%

EPS Next 5Y-19.51%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-12.77%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y61.47%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y61.47%

OCF growth 3YN/A

OCF growth 5YN/A

JUPITER NEUROSCIENCES INC (JUNS) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens